CytRx Corporation (NASDAQ:CYTR) on Mar. 5 reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -4.14% in last session and finished the day at $5.10. Traded volume was 3,687,994 million shares in the last session and the average volume of the stock remained 4.39 million shares. The beta of the stock remained 1.51. CytRx Corporation (NASDAQ:CYTR) insider ownership is 11.30%.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its fourth quarter and full year 2013 financial results. Net loss for 2013 was $130.7 million, or basic and diluted net loss per share available to common stockholders of $1.32, compared with net loss for 2012 of $91.8 million, or basic and diluted net loss per share available to common stockholders of $1.28. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rose percent to $5.91 yesterday on volume of 2.82 million shares. The intra-day range of the stock was $5.43 to $5.99. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has a market capitalization of $608.96 million.

CEL-SCI Corporation (NYSEAMEX:CVM) reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI Corporation (NYSEMKT:CVM)’s stock on Mar 10, 2014 reported a decrease of -2.84% to the closing price of $1.37. Its fifty two weeks range is $ 0.53 -$ 3.09. The total market capitalization recorded $76.64 million. The overall volume in the last trading session was 2,819,394 million shares. In its share capital, CEL-SCI Corporation (NYSEMKT:CVM) has 102.41million outstanding shares.

Roth Capital increased their target price on shares of IGI Laboratories (AMEX:IG) to $5.25 in a research note issued on Friday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. On Monday, shares of IGI Laboratories, Inc. (NYSEMKT:IG) advanced 11.69% to close the day at $4.68. Company return on investment (ROI) is-53.70% and its monthly performance is recorded as 44.44%. IGI Laboratories, Inc. (NYSEMKT:IG) quarterly revenue growth is 46.71%.